RU2603481C2 - Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов - Google Patents

Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов Download PDF

Info

Publication number
RU2603481C2
RU2603481C2 RU2013139727/15A RU2013139727A RU2603481C2 RU 2603481 C2 RU2603481 C2 RU 2603481C2 RU 2013139727/15 A RU2013139727/15 A RU 2013139727/15A RU 2013139727 A RU2013139727 A RU 2013139727A RU 2603481 C2 RU2603481 C2 RU 2603481C2
Authority
RU
Russia
Prior art keywords
antibody
binding fragment
antigen binding
administered
hypercholesterolemia
Prior art date
Application number
RU2013139727/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2013139727A (ru
Inventor
Коринн Анотэн
Лоранс БЕССАК
Умеш ЧАУДХАРИ
Original Assignee
Санофи Байотекнолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45529125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2603481(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP11305089A external-priority patent/EP2481758A1/en
Priority claimed from EP11305088.4A external-priority patent/EP2650016A1/en
Application filed by Санофи Байотекнолоджи filed Critical Санофи Байотекнолоджи
Publication of RU2013139727A publication Critical patent/RU2013139727A/ru
Application granted granted Critical
Publication of RU2603481C2 publication Critical patent/RU2603481C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
RU2013139727/15A 2011-01-28 2012-01-27 Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов RU2603481C2 (ru)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
EP11305089A EP2481758A1 (en) 2011-01-28 2011-01-28 Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
EP11305088.4A EP2650016A1 (en) 2011-01-28 2011-01-28 Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
EP11305089.2 2011-01-28
EP11305088.4 2011-01-28
EP11305514 2011-04-29
EP11305513 2011-04-29
EP11305513.1 2011-04-29
EP11305514.9 2011-04-29
EP11306040 2011-08-12
EP11306039.6 2011-08-12
EP11306039 2011-08-12
EP11306040.4 2011-08-12
EP11306202 2011-09-22
EP11306202.0 2011-09-22
EP11306201.2 2011-09-22
EP11306201 2011-09-22
EP11306449.7 2011-11-08
EP11306450.5 2011-11-08
EP11306449 2011-11-08
EP11306450 2011-11-08
PCT/EP2012/051320 WO2012101252A2 (en) 2011-01-28 2012-01-27 Human antibodies to pcsk9 for use in methods of treating particular groups of subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016142277A Division RU2721279C2 (ru) 2011-01-28 2012-01-27 Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов

Publications (2)

Publication Number Publication Date
RU2013139727A RU2013139727A (ru) 2015-03-10
RU2603481C2 true RU2603481C2 (ru) 2016-11-27

Family

ID=45529125

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2013139736/15A RU2604139C2 (ru) 2011-01-28 2012-01-27 Фармацевтические композиции, содержащие антитела к pcsk9 человека
RU2013139727/15A RU2603481C2 (ru) 2011-01-28 2012-01-27 Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
RU2016142277A RU2721279C2 (ru) 2011-01-28 2012-01-27 Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
RU2016142273A RU2016142273A (ru) 2011-01-28 2012-01-27 Фармацевтические композиции, содержащие антитела к pcsk9 человека

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2013139736/15A RU2604139C2 (ru) 2011-01-28 2012-01-27 Фармацевтические композиции, содержащие антитела к pcsk9 человека

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2016142277A RU2721279C2 (ru) 2011-01-28 2012-01-27 Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
RU2016142273A RU2016142273A (ru) 2011-01-28 2012-01-27 Фармацевтические композиции, содержащие антитела к pcsk9 человека

Country Status (37)

Country Link
US (7) US9561155B2 (OSRAM)
EP (4) EP3395836B1 (OSRAM)
JP (8) JP2014508142A (OSRAM)
KR (6) KR20140006013A (OSRAM)
CN (4) CN107899010A (OSRAM)
AR (3) AR084938A1 (OSRAM)
AU (5) AU2012210481B2 (OSRAM)
BR (2) BR112013018740A2 (OSRAM)
CA (2) CA2825778A1 (OSRAM)
CL (2) CL2013002162A1 (OSRAM)
CO (2) CO6751276A2 (OSRAM)
CR (1) CR20130406A (OSRAM)
CY (1) CY1121236T1 (OSRAM)
DK (1) DK2668212T3 (OSRAM)
DO (1) DOP2013000170A (OSRAM)
EC (1) ECSP13012792A (OSRAM)
ES (3) ES2674600T3 (OSRAM)
GT (1) GT201300186A (OSRAM)
HR (1) HRP20180959T1 (OSRAM)
HU (1) HUE039258T2 (OSRAM)
IL (5) IL227657B (OSRAM)
LT (1) LT2668212T (OSRAM)
MA (1) MA34923B1 (OSRAM)
MX (5) MX366458B (OSRAM)
MY (2) MY176600A (OSRAM)
NI (1) NI201300064A (OSRAM)
PE (2) PE20181052A1 (OSRAM)
PH (3) PH12013501577A1 (OSRAM)
PL (3) PL3326648T3 (OSRAM)
PT (1) PT2668212T (OSRAM)
RS (1) RS57339B1 (OSRAM)
RU (4) RU2604139C2 (OSRAM)
SG (2) SG192118A1 (OSRAM)
SI (1) SI2668212T1 (OSRAM)
TW (3) TWI635870B (OSRAM)
WO (3) WO2012101252A2 (OSRAM)
ZA (2) ZA201305524B (OSRAM)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
MX366458B (es) 2011-01-28 2019-07-10 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
HK1202804A1 (en) * 2011-07-14 2015-10-09 辉瑞公司 Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
MX363642B (es) 2011-09-16 2019-03-28 Regeneron Pharma Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2875096A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
WO2014028354A1 (en) 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP2703008A1 (en) * 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2703009A1 (en) * 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
DK3081249T3 (da) 2012-11-21 2021-03-15 Amgen Inc Lægemiddeladministrationsanordning
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
SG11201507417RA (en) 2013-03-15 2015-10-29 Amgen Inc Body contour adaptable autoinjector device
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
CN113559363B (zh) 2013-03-22 2023-10-31 美国安进公司 注射器及装配方法
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (en) * 2013-06-07 2014-12-10 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
ES2901400T3 (es) * 2013-06-07 2022-03-22 Regeneron Pharma Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9
EP2862877A1 (en) * 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
CN105705521A (zh) 2013-06-07 2016-06-22 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
WO2014209384A1 (en) * 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン
ES2779126T3 (es) * 2013-10-11 2020-08-13 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
CA3168888A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
BR112016008946B1 (pt) 2013-10-24 2022-12-27 Amgen Inc Injetores e método para montar os injetor
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
KR20160115939A (ko) * 2014-02-14 2016-10-06 리제너론 파아마슈티컬스, 인크. 중등-용량 스타틴 치료법에 의해 적당하게 조절되지 않는 고콜레스테롤혈증이 있는 환자의 치료 방법
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015140079A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
JP2017509624A (ja) * 2014-03-17 2017-04-06 サノフィ・バイオテクノロジー 心血管リスクを低減させる方法
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
BR112016025852B1 (pt) 2014-05-07 2022-11-01 Amgen Inc Dispositivo de injeção para aplicação de fármaco
SG11201609966SA (en) 2014-06-03 2016-12-29 Amgen Inc Drug delivery system and method of use
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
KR20230007538A (ko) * 2014-07-16 2023-01-12 사노피 바이오테크놀로지 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
RU2735521C2 (ru) * 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
US10695506B2 (en) 2014-10-14 2020-06-30 Amgen Inc. Drug injection device with visual and audio indicators
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
ES2748750T3 (es) 2015-02-17 2020-03-17 Amgen Inc Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
KR20170123345A (ko) 2015-03-20 2017-11-07 오르후스 우니베르시테트 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
US10548974B2 (en) * 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
WO2017114230A1 (zh) 2015-12-31 2017-07-06 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
CN107531795B (zh) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
EP4035711B1 (en) 2016-03-15 2025-06-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es) 2016-05-13 2024-02-28 Amgen Inc Conjunto de cubierta protectora de vial
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
EP3525820A4 (en) * 2016-10-17 2020-09-16 Vanderbilt University ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS AND THEIR USE METHODS
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
PL3600491T3 (pl) 2017-03-28 2024-03-04 Amgen Inc. Układ i sposób montażu trzonu tłoka i strzykawki
US11325945B2 (en) 2017-04-12 2022-05-10 Cadila Healthcare Limited Peptide based PCSK9 vaccine
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
MX2019015479A (es) 2017-06-23 2020-02-20 Amgen Inc Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
IL272636B2 (en) 2017-10-06 2024-10-01 Amgen Inc Drug delivery device with interlock assembly and related method of assembly
IL273323B2 (en) 2017-10-09 2024-10-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
IL273582B2 (en) 2017-11-03 2024-12-01 Amgen Inc Systems and approaches for sterilizing a drug delivery device
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
EP3710089A1 (en) 2017-11-16 2020-09-23 Amgen Inc. Autoinjector with stall and end point detection
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
CN113015543A (zh) * 2018-03-06 2021-06-22 赛诺菲生物技术公司 Pcsk9抑制剂用于降低心血管风险的用途
WO2019222529A1 (en) * 2018-05-16 2019-11-21 Lib Therapeutics, Llc Compositions comprising pcsk9-binding molecules and methods of use
WO2019225568A1 (ja) * 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CN112351804A (zh) 2018-07-24 2021-02-09 安进公司 用于施用药物的输送装置
MX2021000748A (es) 2018-07-24 2021-03-26 Amgen Inc Dispositivos de suministro para administrar farmacos.
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CA3110529A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
TWI824026B (zh) 2018-10-05 2023-12-01 美商安進公司 具有劑量指示器之藥物遞送裝置
IL313960B2 (en) 2018-10-15 2025-10-01 Amgen Inc Drug delivery device with a suppression mechanism
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
EP3923896A1 (en) * 2019-02-12 2021-12-22 Amgen Inc. Systems and approaches for drug delivery device reconstitution
CA3137360A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
EP4640848A2 (en) 2019-05-17 2025-10-29 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
JP2022551738A (ja) * 2019-10-18 2022-12-13 アムジエン・インコーポレーテツド 薬物送達デバイス再構成のためのシステム及び手法
JP2021041262A (ja) * 2020-12-17 2021-03-18 株式会社三洋物産 遊技機
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2010029513A2 (en) * 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Pcsk9 antagonists

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
AU670793B2 (en) 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
JPH09505721A (ja) 1992-10-20 1997-06-10 シータス オンコロジー コーポレイション インターロイキン６レセプターアンタゴニスト
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
EP0791359A4 (en) 1994-10-21 2002-09-11 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
EP0800829B2 (en) 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
ES2264135T3 (es) 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
CA2250570A1 (en) 1996-03-26 1997-10-02 Eli Lilly And Company Formulations of ob protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP0923941B1 (en) 1996-06-27 2006-05-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
EP1051157B1 (en) 1998-01-30 2002-01-02 Scios Inc. Controlled release delivery of peptide or protein
CA2324115C (en) 1998-03-17 2008-12-23 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
AU7824900A (en) 1999-10-07 2001-04-23 Eli Lilly And Company Compounds and methods for inhibiting mrp1
EP1257572A2 (en) 2000-02-07 2002-11-20 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
CA2421760A1 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2335725B1 (en) 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
JP2008505054A (ja) 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
US20110313024A1 (en) 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008524242A (ja) 2004-12-16 2008-07-10 ジェネンテック・インコーポレーテッド 自己免疫障害を治療する方法
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
WO2007062040A1 (en) 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
CN101489565A (zh) 2006-05-05 2009-07-22 Isis药物公司 调节pcsk9表达的化合物和方法
WO2007134161A2 (en) 2006-05-11 2007-11-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the pcsk9 gene
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2668131A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CN101636179B (zh) 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008133647A2 (en) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2455471A3 (en) 2006-11-27 2012-09-12 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CN101589143A (zh) 2006-11-27 2009-11-25 Isis药物公司 用于治疗高胆固醇血症的方法
JP5100101B2 (ja) 2006-12-12 2012-12-19 キヤノン株式会社 画像形成装置
EP2137218A2 (en) 2007-04-13 2009-12-30 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP5425056B2 (ja) 2007-05-15 2014-02-26 エフ．ホフマン−ラ ロシュ アーゲー Ｇタンパク質共役受容体（ｇｐｃｒ）に対する抗体
US20100286021A1 (en) 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
JP2011501952A (ja) 2007-10-26 2011-01-20 シェーリング コーポレイション 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JP5642683B2 (ja) 2008-09-19 2014-12-17 ファイザー・インク 安定な液体抗体配合物
JP5524967B2 (ja) 2008-09-19 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規抗体処方物
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US20100216667A1 (en) 2008-12-17 2010-08-26 Meyer Brian K Method for determining compatibility of an active pharmaceutical ingredient with materials
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
MX2011013722A (es) 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011028938A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
WO2011039578A1 (en) 2009-10-02 2011-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
US8877900B2 (en) 2009-10-30 2014-11-04 Merck Sharp & Dohme Corp. AX132 PCSK9 antagonists
JP2013509191A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ１およびａｘ１８９ｐｃｓｋ９アンタゴニストおよびバリアント
BR112012012080B1 (pt) 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
DE102010024698A1 (de) 2010-06-23 2011-12-29 Eads Deutschland Gmbh Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
WO2012044999A2 (en) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA2817015A1 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
EA201390929A1 (ru) 2010-12-22 2013-12-30 Дженентек, Инк. Антитела к pcsk9 и способы их применения
MX366458B (es) 2011-01-28 2019-07-10 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AU2012214251A1 (en) 2011-02-11 2013-09-12 Novartis Ag PCSK9 antagonists
US8440890B1 (en) 2011-03-09 2013-05-14 Pioneer Hi Bred International Inc Maize variety inbred PH1D0D
PL2699293T3 (pl) 2011-04-20 2019-08-30 Amgen Inc. Urządzenie do wstrzykiwania automatycznego
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
CA2746171C (en) 2011-07-13 2018-11-06 William Jani Retrievable stimulation frac (rsf) plug
HK1202804A1 (en) 2011-07-14 2015-10-09 辉瑞公司 Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
MX363642B (es) 2011-09-16 2019-03-28 Regeneron Pharma Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
SI2822587T1 (sl) 2012-03-08 2016-04-29 F. Hoffmann-La Roche Ag Farmacevtska oblika abeta protitelesa
HK1207403A1 (en) 2012-04-19 2016-01-29 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013177536A2 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2014028354A1 (en) 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP2703008A1 (en) 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
RU2538801C2 (ru) 2013-02-07 2015-01-10 Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
CN105705521A (zh) 2013-06-07 2016-06-22 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
ES2914978T3 (es) 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
KR20160115939A (ko) 2014-02-14 2016-10-06 리제너론 파아마슈티컬스, 인크. 중등-용량 스타틴 치료법에 의해 적당하게 조절되지 않는 고콜레스테롤혈증이 있는 환자의 치료 방법
JP2017509624A (ja) 2014-03-17 2017-04-06 サノフィ・バイオテクノロジー 心血管リスクを低減させる方法
WO2015140079A1 (en) 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
KR20230007538A (ko) 2014-07-16 2023-01-12 사노피 바이오테크놀로지 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
RU2735521C2 (ru) 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
TW202310872A (zh) 2017-06-09 2023-03-16 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
CN113015543A (zh) 2018-03-06 2021-06-22 赛诺菲生物技术公司 Pcsk9抑制剂用于降低心血管风险的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2010029513A2 (en) * 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Pcsk9 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVIGNON J. et al. "The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis", Curr Atheroscler Rep,2010 Sep;12(5):308-15, реферат, найдено из PubMed PMID:20623344. *

Also Published As

Publication number Publication date
CN103476797A (zh) 2013-12-25
JP2017095491A (ja) 2017-06-01
AR084939A1 (es) 2013-07-10
JP2014511361A (ja) 2014-05-15
CN110711248A (zh) 2020-01-21
US20140154262A1 (en) 2014-06-05
NZ613870A (en) 2015-12-24
CO6751276A2 (es) 2013-09-16
AU2012210480A1 (en) 2013-08-22
JP2017095490A (ja) 2017-06-01
CA2825838A1 (en) 2012-08-02
CO6751277A2 (es) 2013-09-16
US20250064926A1 (en) 2025-02-27
EP2668211A1 (en) 2013-12-04
NZ792724A (en) 2024-07-05
PE20181052A1 (es) 2018-07-03
MX367075B (es) 2019-08-05
EP2668212A2 (en) 2013-12-04
EP3326648B1 (en) 2021-03-10
IL266682B (en) 2021-04-29
ES2882570T3 (es) 2021-12-02
SG192117A1 (en) 2013-08-30
NZ613867A (en) 2015-09-25
ZA201305524B (en) 2014-03-26
MY165159A (en) 2018-02-28
IL265707A (en) 2019-05-30
AU2019229366B2 (en) 2021-09-16
MX366458B (es) 2019-07-10
RU2721279C2 (ru) 2020-05-18
WO2012101253A1 (en) 2012-08-02
HRP20180959T1 (hr) 2018-07-27
CA2825778A1 (en) 2012-08-02
IL227658A0 (en) 2013-09-30
PL3395836T3 (pl) 2021-12-13
BR112013018877A2 (pt) 2016-10-04
NI201300064A (es) 2013-12-17
PL2668212T3 (pl) 2018-08-31
MA34923B1 (fr) 2014-02-01
US11246925B2 (en) 2022-02-15
JP2014508142A (ja) 2014-04-03
IL282219A (en) 2021-05-31
GT201300186A (es) 2014-04-29
IL282219B (en) 2022-03-01
WO2012101251A1 (en) 2012-08-02
SI2668212T1 (en) 2018-08-31
AU2019229366A1 (en) 2019-10-03
IL227657A0 (en) 2013-09-30
PH12013501576A1 (en) 2013-09-30
JP2022141869A (ja) 2022-09-29
MX347602B (es) 2017-05-03
AU2012210480B2 (en) 2017-05-18
ECSP13012792A (es) 2013-09-30
EP3326648A1 (en) 2018-05-30
AU2017216546A1 (en) 2017-09-07
US20220218823A1 (en) 2022-07-14
SG192118A1 (en) 2013-09-30
ZA201305565B (en) 2016-01-27
HUE039258T2 (hu) 2018-12-28
KR20140006013A (ko) 2014-01-15
KR20190090055A (ko) 2019-07-31
MX2019008245A (es) 2019-09-06
US20190343719A1 (en) 2019-11-14
CR20130406A (es) 2013-10-09
CL2013002162A1 (es) 2014-02-21
JP7140800B2 (ja) 2022-09-21
IL227657B (en) 2019-05-30
EP3395836B1 (en) 2021-04-28
US9561155B2 (en) 2017-02-07
TW201242613A (en) 2012-11-01
PE20140372A1 (es) 2014-03-24
AU2012210481B2 (en) 2017-05-18
AU2012210481A1 (en) 2013-08-22
EP3395836A1 (en) 2018-10-31
CL2013002161A1 (es) 2014-03-28
RU2013139736A (ru) 2015-03-10
CN103476796A (zh) 2013-12-25
AU2017216547A1 (en) 2017-09-07
MY176600A (en) 2020-08-18
RU2013139727A (ru) 2015-03-10
JP6375113B2 (ja) 2018-08-15
CA2825838C (en) 2020-10-27
JP6730388B2 (ja) 2020-07-29
MX2013008672A (es) 2013-10-01
US20140178402A1 (en) 2014-06-26
US9682013B2 (en) 2017-06-20
PT2668212T (pt) 2018-06-28
KR20140012075A (ko) 2014-01-29
DOP2013000170A (es) 2013-11-30
WO2012101252A2 (en) 2012-08-02
LT2668212T (lt) 2018-07-10
MX385311B (es) 2025-03-18
RU2016142277A (ru) 2018-12-17
CN107899010A (zh) 2018-04-13
KR20220136466A (ko) 2022-10-07
TWI625127B (zh) 2018-06-01
PH12013501577A1 (en) 2013-09-30
ES2873273T3 (es) 2021-11-03
JP2024138473A (ja) 2024-10-08
AU2017216546B2 (en) 2019-10-03
US20170340515A1 (en) 2017-11-30
HK1255729A1 (en) 2019-08-23
TW201242614A (en) 2012-11-01
AR084937A1 (es) 2013-07-10
DK2668212T3 (en) 2018-07-02
CY1121236T1 (el) 2020-05-29
US20170266079A1 (en) 2017-09-21
TWI635870B (zh) 2018-09-21
BR112013018740A2 (pt) 2019-01-08
KR20190062612A (ko) 2019-06-05
KR20200133826A (ko) 2020-11-30
RU2604139C2 (ru) 2016-12-10
PH12021500018A1 (en) 2021-12-13
AR084938A1 (es) 2013-07-10
PL3326648T3 (pl) 2021-10-11
WO2012101252A3 (en) 2012-11-15
EP2668212B1 (en) 2018-03-21
US12083176B2 (en) 2024-09-10
RU2016142273A (ru) 2018-12-18
RU2016142277A3 (OSRAM) 2020-03-06
IL266682A (en) 2019-07-31
JP2018203772A (ja) 2018-12-27
TW201711698A (zh) 2017-04-01
RS57339B1 (sr) 2018-08-31
MX2013008669A (es) 2013-10-01
ES2674600T3 (es) 2018-07-02
JP2020172514A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
US12083176B2 (en) Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
HK1263065B (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
HK1263065A1 (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
HK1191956B (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
HK1191956A (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant